<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735722</url>
  </required_header>
  <id_info>
    <org_study_id>AF07004AF</org_study_id>
    <nct_id>NCT00735722</nct_id>
  </id_info>
  <brief_title>A(f)MAZE-CABG Study</brief_title>
  <acronym>AFMAZE-CABG</acronym>
  <official_title>A Prospective Randomized Trial Comparing Freedom From Atrial Fibrillation at One Year Post CABG in Patients Undergoing Concomitant Left Atrial Ablation Using HIFU Versus CABG in Patients With Persistent or Long Standing Persistent AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concomitant AF ablation with HIFU in patients with persistent or long standing persistent AF
      undergoing CABG will be superior in restoring SR, compared with patients with persistent or
      long standing persistent AF undergoing CABG treated with best medical treatment according to
      ACC/AHA/ESC 2006 guidelines and no AF ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective

      • To compare the efficacy of concomitant AF ablation using HIFU to no ablation at 12 months
      in patients with persistent or long standing persistent AF undergoing CABG according to
      ACC/AHA/ESC 2006 guidelines and HRS/EHRA/ECAS Consensus Statement on Catheter and Surgical
      Ablation .

      Secondary Objectives

        -  To compare the safety of concomitant AF ablation using HIFU to no ablation in patients
           with persistent or long standing persistent AF undergoing CABG.

        -  To compare AF burden in patients with persistent or long standing persistent AF treated
           with concomitant HIFU AF ablation undergoing CABG to those receiving no ablation.

        -  To compare the quality of life of patients with persistent or long standing persistent
           AF treated with concomitant HIFU AF ablation undergoing CABG to those receiving no
           ablation.

        -  To compare the health economic impact of concomitant AF ablation with HIFU in patients
           with persistent or long standing persistent AF undergoing CABG to those receiving no
           ablation.

        -  To compare the morbidity associated with persistent or long standing persistent AF in
           patients following CABG and ablation compared to those receiving no ablation.

        -  To compare cardiac function and left atrial transport associated with persistent or long
           standing persistent AF patients following CABG and ablation compared to those receiving
           no ablation.

        -  To document the incidence of immediate post ablation bidirectional conduction block
           through the pulmonary venous cinch and mitral lines.

        -  To document the effect of Intra-operative pre and post ablation stimulation and ablation
           of the autonomic ganglia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Atrial Arrhythmias (AF, Atrial Flutter, Atrial Tachycardia) at 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from AF and other atrial arrhythmias at 3, 6, 9 and 18 months post ablation procedure (determined by 24 hour Holter monitor)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from AF and other atrial arrhythmias at 24 months post ablation procedure (determined by 72 hour Holter monitor)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden (determined by 24 and 72 hour Holter monitor).</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity performing concurrent ablation in patients undergoing CABG assessed using length of ICU and hospital stay</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stroke, TIA, PV stenosis, bleeding, thromboembolic complications, subsequent pace maker implantation, and death</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function and dimensions and LA size/transport capability</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of conduction block post ablation both intraoperatively across the pulmonary venous and mitral lines</measure>
    <time_frame>At intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of autonomic ganglia stimulation pre and post ablation intra-operatively</measure>
    <time_frame>Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements (SF-36)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Coronary Artery Bypass Graft Surgery</condition>
  <arm_group>
    <arm_group_label>Concomitant HIFU ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIFU AF Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIFU AF Ablation</intervention_name>
    <description>Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)</description>
    <arm_group_label>Concomitant HIFU ablation</arm_group_label>
    <other_name>• Epicor™ UltraCinch™ LP Ablation Device</other_name>
    <other_name>• Epicor™ UltraWand™ LP Tissue Ablation Wand</other_name>
    <other_name>• Epicor™ LP Positioning and Sizing (LP PAS™) System</other_name>
    <other_name>• Epicor™ LP Oblique Introducer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Legal age in host country

          -  Scheduled for CABG surgery

          -  Patient suffering from persistent or long-standing persistent AF

          -  Patients having the ability to fully comply with the study requirements

          -  Life expectancy &gt; 2 years

          -  Patients who have given written informed consent to participate in the study

        Exclusion Criteria:

          -  Clinically significant local or systemic infection or active endocarditis

          -  Sutures, pacing/defibrillator leads on the left side of the heart, valve prostheses or
             rings, or other implanted material in or adjacent to target treatment area.

          -  Stent in the coronary artery preventing an adequate mitral line

          -  Any other concomitant operation on the heart

          -  Previous heart surgery

          -  Patients who are or may potentially be pregnant

          -  Previous catheter ablation for atrial arrhythmia

          -  LA size more than 60 mm in apical view on Trans-Thoracic Echocardiogram (TTE)

          -  LA thrombus on intra-operative Trans-Oesophageal Echocardiogram (TOE)

          -  Known contraindication to Amiodarone

          -  Inability to undergo TOE

          -  Patients who are unable to give full informed consent for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Dalrymple-Hay, Mr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derriford Hospital, Plymouth, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elisabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Western Finland</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Essen</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig Holstein Campus Luebeck</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feiringklinikken</name>
      <address>
        <city>Feiring</city>
        <zip>2093</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AF</keyword>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

